Due to the advances in use of antisense oligonucleotides (ASOs) in treatment of rare disease, including rare retinal diseases [38], we were interested to test whether an siRNA approach to reducing TTLL5 levels could rescue the ciliogenesis and glutamylation defects observed in AGBL5−/− clones. This evidence concerns the gene AGBL5 and Abnormal retinal morphology.